Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q3 2023 · 10-Q
Revenue$0.00$0.00no prior Q3 2022 on file Net Income-$138.28K-$138.28Kno prior Q3 2022 on file EPS Diluted$0.00$0.00no prior Q3 2022 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,460— ended Oct 31, 2022 · filed Dec 21, 2022 · 51 d after period end